Am Regent Company Profile
What is the competitive landscape for AM REGENT
AM REGENT has eighty-two approved drugs.
There are eleven US patents protecting AM REGENT drugs.
Summary for Am Regent
| US Patents: | 11 |
| Tradenames: | 75 |
| Ingredients: | 72 |
| NDAs: | 82 |
Drugs and US Patents for Am Regent
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-001 | Jul 25, 2013 | AP | RX | Yes | Yes | 7,754,702 | ⤷ Start Trial | ⤷ Start Trial | |||
| Am Regent | TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE | trimethobenzamide hydrochloride | INJECTABLE;INJECTION | 091329-001 | Mar 8, 2011 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Am Regent | TRIMETHOBENZAMIDE HYDROCHLORIDE | trimethobenzamide hydrochloride | INJECTABLE;INJECTION | 091330-001 | Mar 8, 2011 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-001 | Jul 25, 2013 | AP | RX | Yes | Yes | 8,895,612 | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Am Regent
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-004 | Feb 4, 2022 | 11,123,321 | ⤷ Start Trial |
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-001 | Jul 25, 2013 | 11,123,321 | ⤷ Start Trial |
| Am Regent | DEXFERRUM | iron dextran | INJECTABLE;INJECTION | 040024-001 | Feb 23, 1996 | 5,624,668 | ⤷ Start Trial |
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-004 | Feb 4, 2022 | 9,376,505 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Am Regent Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | 507246 | ⤷ Start Trial |
| Canada | 2953964 | ⤷ Start Trial |
| Argentina | 041472 | ⤷ Start Trial |
| Norway | 20052410 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Am Regent Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1453521 | 39/2015 | Austria | ⤷ Start Trial | PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
| 1853250 | PA2014022 | Lithuania | ⤷ Start Trial | PRODUCT NAME: PACLITAXELUM; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220 |
| 1853250 | CA 2014 00034 | Denmark | ⤷ Start Trial | PRODUCT NAME: PACLITAXEL FORMULERET SOM ALBUMINBUNDNE NANOPARTIKLER; REG. NO/DATE: EU/1/07/428 C(2013)9835 20131230 |
| 2666774 | CA 2020 00037 | Denmark | ⤷ Start Trial | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
